Belite Bio (BLTE)
(Delayed Data from NSDQ)
$50.99 USD
+0.09 (0.18%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $50.91 -0.08 (-0.16%) 7:58 PM ET
4-Sell of 5 4
C Value F Growth D Momentum F VGM
Balance Sheet
Fiscal Year End for Belite Bio, Inc Sponsored ADR falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 88 | 42 | 17 | 26 | -99,999 |
Receivables | 1 | 0 | 0 | 0 | NA |
Notes Receivable | 0 | 0 | 0 | 0 | NA |
Inventories | 0 | 0 | 0 | 0 | NA |
Other Current Assets | 1 | 1 | 0 | 0 | NA |
Total Current Assets | 90 | 43 | 17 | 26 | NA |
Net Property & Equipment | 0 | 1 | 0 | 0 | NA |
Investments & Advances | 0 | 0 | 0 | 0 | NA |
Other Non-Current Assets | 0 | 0 | 0 | 0 | NA |
Deferred Charges | 0 | 0 | 1 | 0 | NA |
Intangibles | 0 | 0 | 0 | 0 | NA |
Deposits & Other Assets | 3 | 0 | 0 | 0 | NA |
Total Assets | 95 | 44 | 18 | 26 | NA |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | NA |
Accounts Payable | 0 | 0 | 0 | 0 | NA |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | NA |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | NA |
Accrued Expenses | 3 | 2 | 2 | 1 | NA |
Income Taxes Payable | 0 | 0 | 0 | 0 | NA |
Other Current Liabilities | 0 | 0 | 0 | 0 | NA |
Total Current Liabilities | 4 | 2 | 2 | 1 | NA |
Mortgages | 0 | 0 | 0 | 0 | NA |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | NA |
Convertible Debt | 0 | 0 | 0 | 0 | NA |
Long-Term Debt | 0 | 0 | 0 | 0 | NA |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | NA |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | NA |
Minority Interest (Liabilities) | 0 | 0 | 32 | 32 | NA |
Total Liabilities | 4 | 3 | 33 | 33 | NA |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | NA |
Common Stock (Par) | 0 | 0 | 0 | 0 | NA |
Capital Surplus | 162 | 82 | 12 | 11 | NA |
Retained Earnings | -72 | -40 | -27 | -18 | NA |
Other Equity | 0 | 0 | 0 | 0 | NA |
Treasury Stock | 0 | 0 | 0 | 0 | NA |
Total Shareholder's Equity | 90 | 42 | -15 | -7 | NA |
Total Liabilities & Shareholder's Equity | 95 | 44 | 18 | 26 | NA |
Total Common Equity | 90 | 42 | -15 | -7 | 0 |
Shares Outstanding | 27.60 | 24.80 | NA | NA | NA |
Book Value Per Share | 3.28 | 1.67 | 0.00 | 0.00 | 0.00 |
Fiscal Year End for Belite Bio, Inc Sponsored ADR falls in the month of December.
All items in Millions except Per Share data.
9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 0 | 0 | 88 | 0 | 0 |
Receivables | 0 | 0 | 1 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 0 | 96 | 1 | 56 | 59 |
Total Current Assets | 114 | 96 | 90 | 56 | 59 |
Net Property & Equipment | 0 | 0 | 0 | 0 | 0 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 5 | 5 | 3 | 1 | 2 |
Total Assets | 118 | 101 | 95 | 58 | 61 |
Liabilities & Shareholders Equity | 9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 0 | 0 | 0 | 0 | 0 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 0 | 0 | 3 | 0 | 0 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Total Current Liabilities | 0 | 0 | 4 | 0 | 0 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 4 | 5 | 4 | 5 | 5 |
Shareholders Equity | 9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 0 | 0 | 162 | 0 | 0 |
Retained Earnings | 0 | 0 | -72 | 0 | 0 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 115 | 96 | 90 | 53 | 56 |
Total Liabilities & Shareholder's Equity | 118 | 101 | 95 | 58 | 61 |
Total Common Equity | 115 | 96 | 90 | 53 | 56 |
Shares Outstanding | 29.70 | 29.10 | 27.60 | 27.20 | 24.90 |
Book Value Per Share | 3.86 | 3.32 | 3.28 | 1.94 | 2.24 |